USPTO Examiner LAFAVE ELIZABETH ROSE - Art Unit 1684

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19060201SINGLE-STRANDED END PRESERVING ADAPTORSFebruary 2025March 2026Allow1321YesNo
17929420CHARACTERIZATION AND LOCALIZATION OF PROTEIN MODIFICATIONSSeptember 2022December 2025Allow3910YesNo
17816215METHODS OF GENE ASSEMBLY USING DNAZYMES AND USE IN DNA DATA STORAGEJuly 2022February 2026Allow4331YesNo
17732932BIOLOGICAL SAMPLE CAPTURE WITH MULTIPLEX ANALYSISApril 2022June 2025Allow3820NoNo
17733888UNIVERSAL ADAPTOR FOR SEQUENCINGApril 2022February 2026Abandon4530NoNo
17772117METHOD OF PRODUCING BIOCHIPSApril 2022January 2026Allow4520NoNo
17642849RECOMBINANT TRANSPOSON ENDSMarch 2022February 2026Abandon4701NoNo
17676720MULTIPLEXED ENGINEERED CELLS AND SYSTEMS FOR BIOFUEL PRODUCTIONFebruary 2022January 2026Abandon4710NoNo
17624497NOVEL APPROACH FOR INCREASING CONTRACTILITY IN PATIENTS WITH SYSTOLIC HEART FAILUREJanuary 2022January 2026Abandon4910NoNo
17617070DNA METHYLATION BASED HIGH RESOLUTION CHARACTERIZATION OF MICROBIOME USING NANOPORE SEQUENCINGDecember 2021March 2026Abandon5110NoNo
17543476METHODS FOR MAPPING PERSONALIZED TRANSLATOMEDecember 2021July 2025Allow4310YesNo
17538594METHOD AND SYSTEM FOR DETECTING MTDNA MUTATIONSNovember 2021February 2026Allow5010NoNo
17615311Method for Creating a cDNA Sequencing LibraryNovember 2021November 2025Allow4720NoNo
17456353Systems and Methods to Assess RNA StabilityNovember 2021October 2025Abandon4710NoNo
17509988POLYNUCLEOTIDE MODIFICATION METHODSOctober 2021January 2026Allow5110YesNo
17490549DNA METHYLATION SEQUENCING ANALYSIS METHODSSeptember 2021January 2026Abandon5110NoNo
17600339INTESTINAL BIOMARKERS FOR GUT HEALTH IN DOMESTICATED BIRDSSeptember 2021November 2025Abandon5010NoNo
17593811METHOD FOR IDENTIFYING FUNCTIONAL ELEMENTSSeptember 2021November 2025Abandon5001NoNo
17284734METHOD FOR CONSTRUCTING SEQUENCING LIBRARYSeptember 2021October 2025Abandon5510NoNo
17438571Compartment-Free Single Cell Genetic AnalysisSeptember 2021August 2025Abandon4710NoNo
17473173Methods of Selecting and Detecting Binding PeptidesSeptember 2021February 2026Abandon5320NoNo
17438217Methods for Single Cell Intracellular Capture and its ApplicationsSeptember 2021January 2026Abandon5211NoNo
17466790DNA METHYLTRANSFERASE 1 TRANSITION STATE STRUCTURE AND USES THEREOFSeptember 2021November 2025Abandon5001NoNo
17436398COMPOSITIONS AND METHODS OF TARGETED NUCLEIC ACID ENRICHMENT BY LOOP ADAPTER PROTECTION AND EXONUCLEASE DIGESTIONSeptember 2021September 2025Allow4820NoNo
17434251COMPOSITIONS AND METHODS FOR ENHANCING MUCOSAL IMMUNITYAugust 2021September 2025Abandon4901NoNo
17430530HAPLOTAGGING - HAPLOTYPE PHASING AND SINGLE-TUBE COMBINATORIAL BARCODING OF NUCLEIC ACID MOLECULES USING BEAD-IMMOBILIZED TN5 TRANSPOSASEAugust 2021February 2026Allow5421NoNo
17429250PRODUCTION AND TRACKING OF ENGINEERED CELLS WITH COMBINATORIAL GENETIC MODIFICATIONSAugust 2021January 2026Allow5311NoNo
17427576METHOD OF SEQUENCING NUCLEIC ACID WITH UNNATURAL BASE PAIRSJuly 2021August 2025Abandon4801NoNo
17443909COMBINATORIAL SETS OF NUCLEIC ACID BARCODES FOR ANALYSIS OF NUCLEIC ACIDS ASSOCIATED WITH SINGLE CELLSJuly 2021July 2025Abandon4710NoNo
17369425Microfluidic Devices and Methods for Use Thereof in Multicellular Assays of SecretionJuly 2021December 2025Abandon5320YesNo
17421175METHODS AND KITS FOR GENERATING AND SELECTING A VARIANT OF A BINDING PROTEIN WITH INCREASED BINDING AFFINITY AND/OR SPECIFICITYJuly 2021October 2025Abandon5110NoNo
17416287IDENTIFICATION OF COGNATE PAIRS OF LIGANDS AND RECEPTORSJune 2021December 2025Allow5420NoNo
17312238GENERATING SPATIAL ARRAYS WITH GRADIENTSJune 2021November 2025Abandon5411NoNo
17299323ROLLING CIRCLE AMPLIFICATION METHOD, METHOD FOR PREPARING SEQUENCING LIBRARY, AND DNA NANOSPHERE PREPARED THEREFROMJune 2021August 2025Allow5021YesNo
17243931METHODS OF DRUG SCREENING USING DNA BARCODINGApril 2021February 2026Abandon5710NoNo
17284098METHODS AND REAGENTS FOR ANALYSING NUCLEIC ACIDS FROM SINGLE CELLSApril 2021February 2026Abandon5810NoNo

Appeals Overview

No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.

Examiner LAFAVE, ELIZABETH ROSE - Prosecution Strategy Guide

Executive Summary

Examiner LAFAVE, ELIZABETH ROSE works in Art Unit 1684 and has examined 27 patent applications in our dataset. With an allowance rate of 33.3%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 51 months.

Allowance Patterns

Examiner LAFAVE, ELIZABETH ROSE's allowance rate of 33.3% places them in the 5% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by LAFAVE, ELIZABETH ROSE receive 1.11 office actions before reaching final disposition. This places the examiner in the 12% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by LAFAVE, ELIZABETH ROSE is 51 months. This places the examiner in the 4% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +48.9% benefit to allowance rate for applications examined by LAFAVE, ELIZABETH ROSE. This interview benefit is in the 92% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 100.0% of cases where such amendments are filed. This entry rate is in the 98% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.

Petition Practice

When applicants file petitions regarding this examiner's actions, 0.0% are granted (fully or in part). This grant rate is in the 0% percentile among all examiners. Strategic Note: Petitions are rarely granted regarding this examiner's actions compared to other examiners. Ensure you have a strong procedural basis before filing a petition, as the Technology Center Director typically upholds this examiner's decisions.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 3% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 3% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Consider after-final amendments: This examiner frequently enters after-final amendments. If you can clearly overcome rejections with claim amendments, file an after-final amendment before resorting to an RCE.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.